Amorphous kinase inhibitor formulations and methods of use thereof
US11185535B2 · kind B2 · utility
36Cited by
82References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 19, 2021 |
| Grant date | Nov 30, 2021 |
| Priority date | — |
| Expiry date | Feb 19, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is an amorphous compound represented by Formula (I): and compositions thereof, which are useful in the treatment of disorders related to the activity of the c-KIT and PDGFRα kinases, and oncogenic forms thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.